Hsbc Holdings PLC Lowers Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

Hsbc Holdings PLC reduced its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 41.9% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 33,629 shares of the biopharmaceutical company’s stock after selling 24,300 shares during the quarter. Hsbc Holdings PLC’s holdings in Catalyst Pharmaceuticals were worth $826,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. WINTON GROUP Ltd raised its holdings in Catalyst Pharmaceuticals by 546.7% during the fourth quarter. WINTON GROUP Ltd now owns 353,529 shares of the biopharmaceutical company’s stock worth $8,251,000 after purchasing an additional 298,862 shares in the last quarter. Merit Financial Group LLC purchased a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at approximately $654,000. Wakefield Asset Management LLLP purchased a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at approximately $1,203,000. Universal Beteiligungs und Servicegesellschaft mbH increased its position in Catalyst Pharmaceuticals by 30.0% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 167,763 shares of the biopharmaceutical company’s stock worth $3,913,000 after purchasing an additional 38,695 shares during the period. Finally, Stratos Wealth Advisors LLC increased its position in Catalyst Pharmaceuticals by 21.2% during the 4th quarter. Stratos Wealth Advisors LLC now owns 117,721 shares of the biopharmaceutical company’s stock worth $2,748,000 after purchasing an additional 20,628 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Wall Street Zen cut Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Oppenheimer lowered Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Citigroup cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $35.00 to $31.50 in a research report on Friday, May 8th. Stephens set a $32.00 target price on Catalyst Pharmaceuticals in a report on Thursday, May 7th. Finally, Weiss Ratings upgraded shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Catalyst Pharmaceuticals Price Performance

NASDAQ:CPRX opened at $31.49 on Thursday. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.05 and a 52-week high of $32.56. The stock has a fifty day simple moving average of $31.40 and a 200-day simple moving average of $27.51. The company has a market capitalization of $3.86 billion, a PE ratio of 18.10, a price-to-earnings-growth ratio of 0.96 and a beta of 0.74.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).